<DOC>
	<DOCNO>NCT00737243</DOCNO>
	<brief_summary>This non-randomized Phase II study . Patients determine initial diagnosis carcinoma unknown primary site ( CUP ) treatment select use molecular profile assay . The assay perform paraffin-embedded tumor tissue biopsy specimen . Patients give specific diagnosis ( e.g. , lung , pancreas , colon , breast , renal cell , prostate ovarian cancer ) receive treatment regimen proven activity . If specific diagnosis make molecular profiling assay , empiric chemotherapy paclitaxel , carboplatin , bevacizumab erlotinib administer .</brief_summary>
	<brief_title>Treatment Based Molecular Profiling Diagnosis Carcinoma Unknown Primary Site</brief_title>
	<detailed_description>The primary objective study evaluate impact molecular assay prediction efficacy therapy patient carcinoma unknown primary site ( CUP ) . Investigators use tumor profiling result direct standard , site-specific first-line therapy patient CUP .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Patients must carcinoma unknown primary site follow diagnostic procedure perform unrevealing primary site : Complete medical history physical examination , Complete blood count , chemistry profile , CT scan chest abdomen , Directed evaluation symptomatic area , PET scan ( recommend ) . 2 . Patients must biopsyproven metastatic carcinoma , follow light microscopic histology : Adenocarcinoma , Poorly differentiate adenocarcinoma , Poorly differentiate carcinoma ( patient poorly differentiate carcinoma must immunoperoxidase stain rule treatable malignancy [ e.g. , lymphoma , neuroendocrine carcinoma ] ) , Poorly differentiate squamous carcinoma . 3 . Patients must biopsy material available surgical biopsy , core needle biopsy , fine needle aspiration biopsy provide adequate specimen ( must 40 % tumor ) molecular profile assay . 4 . An ECOG performance status 0 , 1 , 2 . 5 . No previous treatment systemic therapy . 6 . Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) . 7 . Laboratory value follow : WBC 4000/micro L , Platelets 100,000/micro L , Serum bilirubin &lt; 1.5 time institutional upper limit normal ( ULN ) , Serum creatinine &lt; 2.0 mg/dL . 8 . Patients brain metastasis eligible lesion control surgical resection radiation therapy , patient steroiddependent , patient meet eligibility criterion . 9 . Patients must &gt; 4 week major operative procedure . 10 . To eligible TREATMENT portion study , patient must one five follow diagnosis : colorectal , pancreas , NSCLC , ovary , renal cancer . 11 . Patients must able understand nature study give write informed consent . 1 . Patients follow specific syndrome eligible : Patients neuroendocrine carcinoma , Women adenocarcinoma isolate axillary lymph node , Women adenocarcinoma isolate peritoneal involvement , Patients carcinoma involve 1 site , resectable tumor site , Patients squamous carcinoma limit cervical , supraclavicular , inguinal lymph node . 2 . Patients uncontrolled brain metastasis patient meningeal metastasis . 3 . Patients insufficient biopsy material available molecular profile assay . 4 . Women pregnant lactating . All female childbearing potential must negative serum urine pregnancy test within 7 day prior study treatment . 5 . Men woman childbearing potential require use effective method contraception study 6 month end therapy . 6 . Patients receive experimental drug within 28 day start treatment . Exclusion Criteria All Patients Receiving BevacizumabContaining Regimens 1 . Patients history acute myocardial infarction within 6 month , clinically significant cardiovascular disease ( e.g. , unstable angina , New York Heart Association [ NYHA ] grade 2 congestive heart failure [ CHF ] , serious cardiac arrhythmia require medication ) &gt; grade 2 vascular disease . 2 . Patients uncontrolled hypertension ( systolic blood pressure [ BP ] 150 diastolic BP &gt; 100mm Hg ) uncontrolled cardiac arrhythmia . 3 . Prior hypertensive crisis hypertensive encephalopathy . 4 . Patients clinical history hemoptysis ( define bright red blood Â½ teaspoon per episode ) hematemesis within 1 month prior Day 1 . 5 . Patients PEG tube G tube . 6 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study . 7 . Core biopsy minor surgical procedure exclude placement vascular access device , within 7 day prior Day 1 . 8 . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 . 9 . Patients proteinuria ( 1000 mg/24 hour ) screen exclude . A 24hour urine collection require patient ( e.g. , patient whose treatment plan exclude bevacizumab ) ; however , patient receive bevacizumab 1+ proteinuria dipstick urinalysis study entry must subsequent 24hour urine collection . 10 . Patients nonhealing wound , ulcer , long bone fracture . 11 . Patients history bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) . 12 . Patients history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior begin bevacizumab . 13 . Patients history stroke transient ischemic attach within 6 month prior first bevacizumab dose . 14 . Known hypersensitivity component bevacizumab . 15 . Patients history disease , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use novel regimen , might affect result study render subject high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Carcinoma Unknown Primary Site</keyword>
	<keyword>Molecular profiling assay</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
</DOC>